Form 4: Nuvation Bio CMO Exercises Options, Sells Shares

Nuvation Bio's Chief Medical Officer, Liu Dongfang, exercised stock options and subsequently sold 20,000 shares of Class A Common Stock.

Summary

• Liu Dongfang, Chief Medical Officer of Nuvation Bio Inc. (NUVB), engaged in an equity transaction on November 20, 2025.
• Exercised stock options to acquire 20,000 shares of Class A Common Stock at an exercise price of $1.87 per share.
• Immediately sold 20,000 shares of Class A Common Stock at a weighted-average price of $7.0037 per share.
• The sale price for the shares ranged from $7.00 to $7.005.
• Following these transactions, Liu Dongfang directly beneficially owns 18,000 shares of Class A Common Stock.
• Liu Dongfang also holds 450,000 stock options (right to buy) after the reported transactions.

Sentiment

Score: 6

Explanation: The transaction reflects an executive monetizing vested options, a common practice for compensation and liquidity. The sale at a higher price than the exercise price is positive for the executive. While an insider sale can sometimes be viewed neutrally to slightly negatively, this 'exercise and sell' transaction is often less impactful than an outright sale of existing holdings, as it's a routine part of equity compensation.

Positives

• The Chief Medical Officer exercised options, indicating the value of the stock at the exercise price of $1.87.
• The sale of shares at a significantly higher weighted-average price of $7.0037 than the exercise price demonstrates a substantial personal gain for the executive.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived neutrally to slightly negatively by the market.
• The transaction reduced the Chief Medical Officer's direct beneficial ownership of Class A Common Stock from 38,000 shares (after exercise) to 18,000 shares.

Future Outlook

This filing, a Form 4, reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report is specific to an executive's equity activity and does not provide broader insights into industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale by a Chief Medical Officer could be interpreted in various ways; some might see it as a routine liquidity event, especially given the exercise of options, while others might question the executive's confidence. The executive still retains a significant number of options, maintaining alignment with shareholder interests.

Next Steps

• Remaining stock options will continue to vest monthly over the 36 months following February 29, 2025, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Medical Officer exercised stock options and immediately sold the acquired shares. This is a common 'exercise and sell' transaction, likely for liquidity or tax purposes, rather than a signal of a change in company fundamentals or outlook. The executive still retains a significant number of options, maintaining alignment with shareholder interests. Without additional context from other filings, this specific transaction alone does not warrant a change from a 'hold' recommendation.

Keywords

Nuvation Bio, NUVB, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Chief Medical Officer, Liu Dongfang, Equity Transaction